ALBTライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (21 5月 2024 @ 05:00):

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China...

Stats
本日の出来高	24 323.00
平均出来高	190 072
時価総額	3.42M
EPS	$0 ( 2024-04-02 )
次の収益日	( $0 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.190
ATR14	$0.00900 (2.92%)

Insider Trading

Date	Person	Action	Amount	type
2021-11-01	Tauzin W J	Buy	8 000	Stock Option (right to buy)
2021-05-01	Tauzin W J	Buy	8 000	Stock Option (right to buy)
2022-05-01	Tauzin W J	Buy	8 000	Stock Option right to buy)
2022-11-01	Tauzin W J	Buy	8 000	Stock Option (right to buy)
2022-01-01	Tauzin W J	Buy	4 000	Stock Option (right to buy)

INSIDER POWER
99.83
Last 100 transactions
Buy: 44 704 561 \| Sell: 8 187 803

ボリューム相関

長: -0.27 (neutral)

短: 0.48 (neutral)

Signal:(56.49) Neutral

Avalon GloboCare Corp. 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Avalon GloboCare Corp. 相関 - 通貨/商品

-0.49
( neutral )

-0.48
( neutral )

0.00
( neutral )

-0.09
( neutral )

Avalon GloboCare Corp. 財務諸表

Annual	2023
収益:	$1.26M
総利益:	$202 789 (16.15 %)
EPS:	$-1.590

FY	2023
収益:	$1.26M
総利益:	$202 789 (16.15 %)
EPS:	$-1.590

FY	2022
収益:	$1.20M
総利益:	$272 728 (22.69 %)
EPS:	$-1.360

FY	2021
収益:	$1.39M
総利益:	$414 518 (29.80 %)
EPS:	$-1.100

Financial Reports:

No articles found.

Avalon GloboCare Corp. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Avalon GloboCare Corp.

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.